

Access PK and biodistribution simultaneously

(Quarterly Newsletter / April 2022)



Dear Customers, Partners & Colleagues,

We wish you a bright, warm, and beautiful Spring! We are elated to share with you ImaBiotech's recent updates, activities and publications in order to support key decisions in drug development.


Enjoy your read & the sunny days to come!

The ImaBiotech team

IN THE NEWS

February 2022, ImaBiotech launches an Innovative Bioanalysis Service including drug distribution to quantify drug and metabolites in plasma and tissues.

This cost-effective bioanalysis service that combines robust mass spectrometry based bioanalytical method allows to select the right dose, the right route of administration, anticipate on/off-target engagement and finally accelerate your drug discovery and development programs.



ImaBiotech helps you make **Decisive Selection and Development** of your leads from discovery stage and includes:

- GLP and non GLP platforms.
- Mass Spectrometry Expertise with +20 years of experience in regulated bioanalysis
- Mass Spectrometry Imaging leader team with proprietary technology and softwares
- Very fast turnaround time (4 weeks) with 40 MS platforms


[Learn more](#)

March 2022, ImaBiotech introduces novel panel to its Imaging Mass Cytometry services to advance biomarker discovery and therapeutic development

ImaBiotech unveils its “Immune Signature Panel” as part of its Imaging Mass Cytometry Services. The new panel will be presented in exclusivity at the #AACR22 meeting in New

Orleans where ImaBiotech is holding the booth #825 in the exhibit hall.

ImaBiotech pioneered Imaging Mass Cytometry (IMC) applications for Biopharma launching its service in 2020. As a leading-edge technology, IMC enables highly multiplexed immunohistochemistry (mIHC) with simultaneous detection of up to 40 protein markers in the same tissue section with subcellular, single cell resolution.



**Press statement from Jonathan Stauber,
CEO of ImaBiotech Group**

We are really pleased to pursue cutting-edge technology that can positively affect patient lives and our Imaging Mass Cytometry capability is a reflection of our dedication to service excellence



[Learn More](#)

May 2022, SID annual meeting

ImaBiotech will be exhibiting at the Society for Investigative Dermatology (SID) Annual Meeting from May 18th to 21st in Portland, Oregon.

SID ANNUAL MEETING
PORTLAND 22
MAY 18-21, 2022

**REGISTRATION
NOW OPEN!**

**Oregon Convention Center
Portland, Oregon**


June 2022, ASMS Conference

Representing ImaBiotech, the Director of R&D, Corinne Ramos will be giving an in-person oral presentation on “Correlations between drug response and tumor microenvironment in early-stage Lung cancer using Imaging Mass Cytometry” and will also be presenting a poster “Immune response adaptation to metabolomic heterogeneity identified with Uniform Manifold Approximation and Projection (UMAP) “at the American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics on June 9th




**PUBLICATIONS
AND PRESS**

Publication: Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial



[Download Publication](#)

Application Note: Cell deconvolution to estimate cell type abundance from Spatial Transcriptomic data within Heterogeneous tissues



[Download Application Note](#)

WEBINAR SERIES

The Growing Application of Spatial Multi-Omics for the Identification of Biomarkers Opens New Doors in Cancer Drug Development

In February, As part of Imabiotech’s webinar series, Corinne Ramos, Innovation director, discussed the use of Fluidigm’s Hyperion platform (Imaging Mass Cytometry Services) and GeoMx® NanoString platform for biomarkers discovery and

predicting response to a given treatment. This webinar also highlighted the advantage of using such high multiplex technologies in routine analysis to obtain faster throughput in a GLP-like environment.

WEBINAR
The Growing Application of Spatial Omics for the Identification of Biomarkers Opens New Doors in Cancer Drug Development

REGISTER NOW

February 10, 2022 / 4:00 PM (CET) / 10:00 AM (EST)

Corinne Ramos, Ph.D.
Director of Innovation

[View the Replay](#)

OUR RESOURCES

STAY UPDATED WITH OUR INFORMATIVE RESOURCES!

We offer online resources to help you gain insights on innovative spatially resolved technologies and services to accelerate drug development.

[Read more](#)

Learn about ImaBiotech's offer on next level phenotype and biomarkers analyses with very High multiplexed immunohisto-staining (mIHC) services to deeply interrogate tissues and tumors at subcellular resolution while preserving the information in tissue architecture and cellular morphology.

[Learn more](#)

Follow ImaBiotech: www.imabiotech.com

To contact us: contacts@imabiotech.com



CONTACT US

if any questions, comments or inquiries ?

and for more information on Bioanalysis and Spatial Bioanalysis